Microvesicle Subsets in Sepsis Due to Community Acquired Pneumonia Compared to Faecal Peritonitis. by Lashin, HMS et al.
Microvesicle subsets in sepsis due to community acquired pneumonia compared to faecal peritonitis

Hazem MS Lashin MD PhD1, 3, Suchita Nadkarni PhD1, Silvia Oggero MSc1, Hefin R Jones MPharmacol1, Julian C Knight MD DPhil2, Charles J Hinds MD PhD1,3, Mauro Perretti PhD1

1William Harvey Research Institute, Barts and the London School of Medicine, Queen Mary University of London, London, United Kingdom; 
2 Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
3Department of Critical Care, Barts Health NHS Trust, London, United Kingdom

Key words: Alpha-2-Macroglobulin, microvesicles, pneumonia, sepsis, peritonitis

Running title: Protective microvesicles in sepsis

Correspondence:




Conflict of interest and Funding
This work was supported by The Wellcome Trust and the William Harvey Research Foundation to MP, the United Kingdom Intensive Care Society to CJH, The Wellcome Trust and the European Research Council to JCK. HMSL was supported by HCA Hospitals UK. This work forms part of the research themes contributing to the translational research portfolio of Barts and the London Cardiovascular Biomedical Research Centre, which is supported and funded by the National Institutes for Health Research.

Conflict of interest
Hazem MS Lashin MD PhD: No conflict of interest
Suchita Nadkarni PhD: No conflict of interest 
Silvia Oggero MSc: No conflict of interest 
Hefin R Jones MPharmacol: No conflict of interest 
Julian C Knight MD DPhil: No conflict of interest 
Charles J Hinds MD PhD: No conflict of interest 
Mauro Perretti PhD: No conflict of interest

Acknowledgement















Rationale: Microvesicles (MV) act as a non-soluble means of inter-cellular communication, with effector roles in disease pathogenesis and potentially as biomarkers. Previously, we reported that neutrophil MV expressing alpha-2-macroglobulin (A2MG) are protective in experimental sepsis and associate with survival in a small cohort of patients with sepsis due to community acquired pneumonia (CAP).
Objectives: To characterise MV profiles in sepsis due to CAP or faecal peritonitis (FP) and determine their relation to outcome. To investigate the effects of novel sepsis treatments (granulocyte-macrophage colony stimulating factor (GM-CSF) and interferon-Υ (IFN-γ)) on MV production and functions in-vitro.
Methods: Flow cytometry analysis of MV identified the cell of origin and the proportion of A2MG expression in the plasma of patients with sepsis secondary to CAP (n=60) or FP (n=40) and compared to healthy volunteers (HV, n=10). The association between MV subsets and outcome was examined. The ability of GM-CSF and IFN-γ on A2MG+ve MV production from whole blood was examined together with the assessment of their effect on neutrophil and endothelial functions. 
Results: Circulating cell-derived and A2MG+ve MV were higher in CAP compared to FP and HV. A2MG+ve MV were higher in survivors of CAP, but not in FP. GM-CSF and IFN-γ enhanced A2MG+ve MV production, with these MV eliciting pathogen clearance in vitro.
Conclusions: Plasma MV profiles vary according to the source of infection. A2MG+ve MV are associated with survival in CAP but not FP. We propose specific MV subsets as novel biomarkers in sepsis and potential effector for some of the actions of experimental therapeutic interventions.

Introduction.
The incidence of sepsis continues to increase and the associated morbidity and mortality remain persistently high1, 2. Lack of progress in combating sepsis reflects our limited understand of the complex biological pathways that regulate immune responses3. It is now recognised that the immune dysfunction evident in many patients with sepsis is associated with a predominant anti-inflammatory response that drives further morbidity and mortality4. Novel strategies to reverse this immune-paresis, such as granulocyte macrophage colony-stimulating factor (GM-CSF) and interferon gamma (IFN-γ)5, 6 7, are therefore being investigated.

An appropriately regulated host response relies on effective cell‐to‐cell communication. A novel means of non‐soluble communication has recently emerged centred on plasma membrane‐shed particles, called microvesicles (MV). MV are heterogeneous, submicron packages surrounded by an outer membrane with surface proteins derived from the parental cell8. In sepsis, MV may display both pro‐ and anti-inflammatory properties9, 10. This heterogeneity resulted in conflicting reports regarding the relation between circulating levels of MV and outcome10, 11.  Our group reported that neutrophils produce distinct MV phenotypes in response to specific activation stimuli12. We found that neutrophil MV expressing the protein alpha-2-macroglobulin (A2MG) promote a pro-inflammatory phenotype when incubated with innate immune cells, as well as improving pathogen clearance and overall survival in a murine model of peritonitis13. Increased levels of A2MG+ve MV were associated with survival in patients with sepsis and organ dysfunction due to community acquired pneumonia (CAP)13.

In this study, we extend these findings to a larger cohort of patients with sepsis due to CAP or faecal peritonitis (FP), performing more detailed analyses of MV profiles including temporal quantification. We also investigated whether the A2MG+ve ‘beneficial’ subset of MV could be produced in whole blood treated with granulocyte-macrophage colony-stimulating factor (GM-CSF) or interferon γ (IFN-γ) and further examined their functional effects in vitro.
Methods
An extended version is available in an on-line supplement (Supplemental Digital Content 01)
Patients and samples.	Patients with sepsis as defined by the third international consensus definitions for sepsis and septic shock (infection with organ dysfunction)14 secondary to CAP or FP (definitions are detailed in Supplemental Digital Content 01) were recruited to the UK Genomic Advances in Sepsis (GAinS) study. Blood was collected on days 1, 3 and 5 post admission to the intensive care unit (ICU). Ethics approvals are detailed in the supplement. Patients were included in this study sequentially in order of recruitment to the GainS study taking into account the amount of sample available for analysis.

Characterization of plasma MV.	Platelet-free plasma (PFP) obtained by differential centrifugation was incubated with selected monoclonal antibodies (Supplemental Digital Content 02) and annexin V (Supplemental Digital Content 03) for 30 minutes. Samples were acquired using a BD LSRFortessa™ flow-cytometer. The Flowjo™ software package was used for data analysis. 

Gating strategy:  Calcium free medium and isotype controls were used to determine non-specific binding for annexin V and monoclonal antibodies respectively (Figure 1B, 2A-B). The MV quantification formula was
N x (D/V) = MV / μL
Where N is the total number of events acquired, V is the sample volume (30μL) and D is the dilution (1 in 40).

MV preparation from whole blood. Blood aliquots (1ml) from HV were incubated with or without GM-CSF or IFN-γ at 37oC. At different time-points, MV were separated and concentrated by centrifugation.

Human umbilical cord endothelial cells (HUVEC) MV uptake. MV labelled with BODIPY were incubated with HUVEC for 4 hours. In some experiments, HUVEC were pre-incubated with cytochalasin B (10μM). Imagestream™ X-II with confirmation by confocal microscopy (Zeiss Laser LSM 710™) was used to detect the presence of MV inside the HUVEC. 

HUVEC functional assays. Adhesion molecule and tissue factor expression were quantified by flow cytometry, following incubation with MV in the absence or presence of lipopolysaccharide (LPS). Reactive oxygen species (ROS) and nitric oxide (NO) production were quantified using 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) and Griess reagent, respectively. Supernatants were tested for IL-8 concentration using ELISA. The permeability of confluent HUVEC on 0.2µm tissue culture inserts was measured by the recovery of FITC-labelled Dextran.

Neutrophil functional Assays. CD11b expression was quantified using flow-cytometry (Supplemental Digital Content 04). ROS production was assessed using H2DCFDA and phagocytosis was tested following incubation with BODIPY-labelled Escherichia coli. The chemotaxis assay was conducted as previously described15: neutrophils were incubated with MV in the presence or absence of LPS (100ng/ml). Formyl-Methionyl-Leucyl-Phenylalanine (1µM) was used as the chemoattractant. In some assays a neutralizing monoclonal antibody against Alpha-2-macroglobulin (A2MG) was added.





One hundred patients recruited to the Genomic Advances in Sepsis study with sepsis due to CAP (n=60) or FP (n=40) were included in this study. Patients were selected to include equal number of survivors and non-survivors (at 28 days post-admission to intensive care unit, ICU). The baseline demographic characteristics, co-morbidities, severity scores and cell counts on admission to ICU were comparable between the two cohorts (Supplemental Digital Content 05). HV were significantly younger than both patient groups and their neutrophil count was significantly lower, while their monocyte and lymphocyte counts were higher.  CAP and FP non-survivors were older and had higher severity scores on admission (Supplemental Digital Content 06 and Supplemental Digital Content 07, respectively) compared to survivors. There were no significant differences in differential leucocyte counts between survivors and non-survivors in either cohort (Supplemental Digital Content 06 and Supplemental Digital Content 07).  

Characterization of plasma MV.
MV phenotype was investigated by flow cytometry in a gate formulated using fluorescent beads of known diameter (0.1 and 1 micron) and focusing on vesicles expressing phosphatidylserine, hence able to bind Annexin V: Figure 1A-C provide representative images for this strategy. At day one post-admission to ICU, the number of neutrophil-, monocyte- and lymphocyte-derived MV were significantly higher in CAP compared to FP patients and HV (Figure 1d-f). MV numbers in FP were not significantly different to HV (Figure 1); platelet- and erythrocyte-derived MV did not differ significantly between the three cohorts. MV derived from endothelial cells were significantly elevated in CAP patients compared to HV, but not FP compared to HV (Figure 1i).  We then characterised MV according to their surface expression of A2MG. Figure 2A-B illustrates how the identification was conducted, using CD41 staining for platelet derived MV as an example. At day 1, the number of total A2MG+ve MV derived from all cellular sources was significantly higher in CAP compared to FP patients and HV (Figure 2c). Further analyses demonstrated that A2MG+ve MV derived from each cell types were all significantly higher in CAP compared to FP and HV (Figure 2d-h). 

MV profiles in CAP survivors and non-survivors.
We proceeded to investigate the relationship between MV subsets and survival in sepsis. In patients with CAP, endothelial MV numbers were significantly higher in non-survivors. There were no significant differences in the other MV subsets between CAP survivors and non-survivors (Supplemental Digital Content 08). When MV were further stratified according to A2MG expression, the total number of A2MG+ve MV from all sources was two-fold higher in CAP survivors compared to non-survivors (Figure 3a). In particular, neutrophil- and monocyte-derived A2MG+ve MV were two- and seven-fold higher in CAP survivors than in non-survivors, respectively (Figure 3b-c), with no significant differences for the other subsets (Figure 3d-f).  FP non-survivors displayed three- and two-fold higher levels of neutrophil- and erythrocyte-derived MV in comparison to survivors, respectively (Supplemental Digital Content 09). Erythrocyte derived A2MG+ve MV were also significantly higher in non-survivors of FP (Supplemental Digital Content 10). 

Subsequently, we characterised MV profiles in the plasma of CAP patients at day 3 and 5 post admission to ICU to establish whether the day 1 MV profile is sustained as the disease progresses. This analysis indicated that the differences between survivors and non-survivors persisted; survivors of CAP exhibited higher levels of A2MG+ve MV derived from neutrophils and monocytes, as well as higher total A2MG+ve counts. No differences were evident when comparing lymphocyte, endothelial and platelet A2MG+ve MV phenotypes (Supplemental Digital Content 11 and Supplemental Digital Content 12). 

Modulation of A2MG+ve MV production by GM-CSF and IFN-γ.
Next, we questioned whether the specific subsets of MV which discriminated between survivors and non-survivors in CAP could be modulated by novel potential therapies for sepsis. The effect of GM-CSF and IFN-γ on whole blood production of A2MG+ve MV was investigated. Preliminary analyses were undertaken to elucidate the optimum incubation times and concentration with respect to A2MG+ve MV production (Figure 4a). The optimal conditions were 30 min following stimulation with 100 ng/ml for GM-CSF and 3h following stimulation with 50 ng/ml IFN-γ. 

Effect of MV derived from GMCSF or IFN-γ stimulated whole blood on endothelial cells and neutrophil responses.
To test whether HUVEC internalised MV, MV from cytokine-stimulated whole blood were labelled with the fluorescent dye BODIPY and incubated with the cells, with or without cytochalasin B. More than 85% of HUVEC endocytosed the fluorescent MV, but this rate of internalisation was reduced to 15% in the HUVEC pre-treated with cytochalasin B. Uptake of MV was confirmed using confocal microscopy demonstrating that HUVEC contain fluorescent MV following 2h incubation (Figure 4; Supplemental Digital Content 13).

Next, we tested the effect of MVs derived from GMCSF or IFN-γ-stimulated whole blood on HUVEC responses in the presence or absence of LPS. The MV did not alter either ICAM-1 or VCAM-1 expression following 4h of incubation with LPS (Supplemental Digital Content 14).  Similarly, expression of CD62E or CD31 was not altered by exposure to cytokine-elicited MV (data not shown). 

In contrast, incubation of HUVEC with GM-CSF-stimulated MV, but not IFN-γ-stimulated MV, significantly enhanced reactive oxygen species (ROS) production both in the presence and absence of LPS (Supplemental Digital Content 15). Both MV populations reduced the increase in HUVEC monolayer permeability induced by LPS (Figure 5).  

Production of endothelial-derived mediators was then measured. Nitric oxide (NO) release was significantly enhanced by both GM-CSF and IFN-γ MV when added to HUVEC in the presence of LPS (Supplemental Digital Content 16). Similarly, both MV populations augmented the release of IL-8, irrespective of LPS addition (Supplemental Digital Content 17). 

Next, we tested the effects of MV on neutrophil functions. GM-CSF- and IFN-γ-derived MV upregulated cell-surface expression of CD11b (Supplemental Digital Content 18). This effect was accompanied by enhanced phagocytosis (Figure 5a). Neutrophil ROS production and chemotaxis were not modified by either MV subset, irrespective of the presence or absence of LPS (Supplemental Digital Content 19 and Supplemental Digital Content 20). To test whether A2MG expressed on MV was contributing to some these effect, an anti-A2MG blocking antibody was used. The antibody, tested at 0.1-5 µg/ml, abrogated the enhancing effect of GM-CSF-derived MV on neutrophil phagocytosis at the maximal concentration tested (Figure 5b). Such an enhancing effect on phagocytosis was not mimicked by soluble factors as it is absent in GM-CSF-treated plasma following removal of MV (Figure 5b).  

Finally, we investigated whether GM-CSF and IFN-γ stimulated MV could affect neutrophil-endothelial interaction under flow conditions, since this phenomenon is known to be modulated by soluble and MV-associated A2MG13. The addition of LPS alone to HUVEC promoted interaction with flowing neutrophils; addition of GMCSF and IFN-γ stimulated MV, but not MV from paired unstimulated blood, enhanced neutrophil capture, rolling, adhesion and transmigration (Figure 5). 

Discussion
In this study of patients with infection and organ dysfunction, CAP and FP plasma samples displayed different MV profiles. Higher levels of A2MG+ve MV were quantified in survivors of sepsis secondary to CAP, an association that was not apparent in those with FP. These findings highlight the increasingly recognised heterogeneity of the septic response, in this case related to the infectious aetiology, despite the similarity of the two cohorts in terms of demographics, co-morbidities, severity scores and cell counts. The observed differences between survivors and non-survivors of CAP may reflect the capacity of the A2MG+ve MV subset to promote potentially beneficial immune responses13. These results may indicate that approaches aiming at stimulating the immune system may represent a valid therapeutic option. Of note, therefore, was the ability of two recently trialled therapies, GM-CSF and IFN-γ, to augment production of this subset of MV, with at least partial validation of A2MG functional role on some of the effects promoted by cytokine-stimulated MV on enhanced pathogen clearance functions of endothelial cells and neutrophils in vitro.  

Previous attempts to profile MV in sepsis have yielded conflicting results11, 16, 17, 18:  Platelet-derived MV are elevated in sepsis compared to HV10, 18 albeit this outcome is not observed consistently11, while endothelial-derived MV are either elevated18, similar19 or even lower16 as compared to HV samples. Numbers of monocyte-derived MV could be either no different to HV10, 18 or could not be detected20. In relation to the outcome of sepsis, it has been reported in heterogeneous cohorts that endothelial-derived MV are elevated in survivors, whereas there were no significant differences between survivors and non-survivors for platelet-derived MV11.  We believe these inconsistent findings may be due to the inclusion of patients with a variety of infectious aetiologies and differences in methodology. In the present study MV numbers in FP patients were only modestly increased when compared to HV, whereas more significant changes were observed in CAP patients, particularly in the granulocyte and monocyte MV subsets despite similar illness severity as determined by APACHE II score. We also identified a specific MV (A2MG+ve) subset that was associated with survival selectively in CAP sepsis.  Importantly, these differences in MV subsets could not be ascribed to changes in circulating parent cells, hence it is plausible that the activation status of the cells, rather than their absolute number, determines the concentration of specific MV in the circulation. 

It is possible that the differences between the MV profiles observed in CAP and FP patients might be due to differences in the time course of each disease. CAP patients have often been unwell for many days prior to ICU admission whereas FP patients usually have a rapid and fairly recent onset of illness. Also, CAP is caused by specific bacterial or atypical pathogens and is commonly preceded, or caused by viral infection21. The majority of causative organisms in CAP are Gram positive22 while FP is due to peritoneal contamination with a mixture of Gram negative, Gram positive and anaerobic organisms23. In FP, the concentration of cytokines is much higher in the peritoneal cavity compared to plasma, suggesting that there is a considerable degree of compartmentalisation that may have little impact on the production of plasma MV24. The host response may also be modulated by surgical trauma in FP patients and the choice of antibiotics25, 26.

The extended analyses presented here indicate that in CAP, A2MG+ve MV are significantly elevated not only for the fraction of MV derived from neutrophils but also in those derived from erythrocytes, platelets, lymphocytes and monocytes. This acute phase protein inhibits proteases and sequesters cytokines such as TNF-α and IL-6, facilitating their endocytosis27. Cytokine binding may underlie the ability of A2MG to enhance survival of endotoxaemic mice28. However, in a recent study conducted in experimental animals, we demonstrated that MV-incorporated A2MG activates specific innate immune responses, such as neutrophil activation and recruitment, responsiveness to IL-8 and phagocytosis13. Although A2MG production in the liver would be expected to increase in sepsis, it is unclear how this acute phase protein becomes incorporated into MV. We reasoned that – similar to albumin – A2MG may be part of the secretory vesicles and as such be present on the cell plasma membrane when MV bud from it13. In any case, coupled with our previous study13 where a limited number of patient samples were analysed, these new data highlight the importance of characterising MV for at least two markers to identify potential associations with disease phenotypes.

The increased expression of A2MG+ve MV in survivors of CAP sepsis persists into day 3 and 5 post admission. However, we cannot ascertain whether this observation reflects the sustained production of A2MG from the liver or whether it is linked to the encapsulation of this protein in the MV, thereby promoting the optimal delivery and bio-actions, or both.  

An important function of MV is to transfer their constituents into target cells. In murine models, neutrophil-derived pro-inflammatory MV can deliver A2MG into macrophages or deposit this acute phase protein onto endothelial monolayers13.  The mechanism for MV internalisation is via phagocytosis or macropinocytosis29. We present evidence here that endothelial cells internalised MV, a cellular uptake largely prevented by cytochalasin B which inhibits actin filament polymerisation30.

Altogether these results identify  A2MG+ve MV as a useful marker associated with better outcome in   CAP sepsis. To establish if this could also have prognostic value for patient responsiveness to novel treatments for sepsis, we tested the effect of GM-CSF and IFN-γ on MV production and function in vitro. We found that both cytokines augmented A2MG+ve MV production when incubated with whole blood. In functional terms, MV produced from whole blood stimulated by GM-CSF or IFN-γ, enhanced IL-8 release, an effect more marked in the presence of LPS.  In clinical trials, GM-CSF and IFN-γ restored TNF-α levels, thereby sustaining the immune response to endotoxin in patients with sepsis, and reducing the incidence of hospital-acquired infection5, 31 32, 33. In sepsis, IL-8 production from whole blood stimulated with endotoxin is inhibited34, a response that could be restored by GM-CSF31 consistent with our data. Moreover, NO production was augmented by stimulated MV; intriguingly, this effect was associated with a reduction in endothelial permeability. MV from stimulated whole blood did not, however affect neutrophil chemotaxis or ROS production. Both GM-CSF and IFN-γ derived MV increased the interaction between neutrophils and endothelial monolayers under flow, extending data produced with neutrophil derived A2MG+ MV which also enhance bacterial clearance and resolution of inflammation in a murine model of sepsis12, 13. In assays of phagocytosis, GM-CSF and IFN-γ-derived A2MG+ MV promoted bacteria engulfment; in these settings we provided proof of concept for the functional involvement of A2MG through the use of an anti-A2MG antibody. 
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Legends to the Figures

Figure 1. Microvesicle (MV) subsets in patients with sepsis secondary to community acquired pneumonia (CAP) or faecal peritonitis (FP) at day 1 post admission to ICU. (A) MV flow-cytometry gate established by back-gating 0.1 and 1 μm fluorescent latex beads. (B) Flow-cytometry dot plot of MV double positive for Annexin V (AV) and alpha-2-macroglobulin (A2MG) (C) Annexin V staining in the gated MV population. Dark grey histogram: no AV; light grey histogram: Annexin V+ve staining. (D–I) Cell derived MV CAP, FP and healthy volunteers (HV) (n=60, 40, 10, respectively). Data expressed as median and Kruskal-Wallis and Dunn’s tests were used for comparisons. *: p<0.05, **: p<0.01. ***: p<0.001. 

Figure 2. Alpha-2-macroglobulin (A2MG) positive microvesicles (MV) in patients with sepsis  secondary to community acquired pneumonia (CAP) or faecal peritonitis (FP) at day 1 post admission to ICU. (A) CD41 expression in the Annexin V (AV)+ve MV population. Dark grey histogram: no CD 41; light grey histogram: CD41+ve staining. (B) A2MG expression in the AV+ve/CD41+ve MV population. (C) Total A2MG+ve MVs comparing CAP, FP and HV (n=60, 40, 10, respectively). (D-H) A2MG+ve cell derived MVs from the same cohorts. Data expressed as median and Kruskal-Wallis and Dunn’s tests were used for comparison. *: p<0.05, **: p<0.01. ***: p<0.001.

Figure 3. Alpha-2-macroglobulin (A2MG) positive microvesicles (MV) subsets in patients with sepsis secondary to community acquired pneumonia (CAP) at day 1 post admission to ICU: comparison between 28 Data expressed as median and Mann Whitney test was used for comparisons (n=60).  AV: annexin V. *: p<0.05. **: p<0.01.

Figure 4. Alpha-2-macroglobulin (A2MG) positive microvesicles generated by blood incubation with granulocyte-macrophage colony stimulating factor (GM-CSF) or interferon-γ (IFN-γ) and are taken up by human umbilical vein endothelial cells (HUVEC). (A) Total A2MG+ve MV production in response to increasing concentrations of GM-CSF or IFN-γ (n=4), incubated for the indicated optimal time as identified in preliminary analyses. (B) Percentage of HUVEC up-taking fluorescent MV produced from whole blood stimulated with GM-CSF or IFN-γ. Imaging flow-cytometry was used for analysis (ImageStreamX™) following 240 min incubation. Cytochalasin B (10 μm) was added to HUVEC 10 min prior to incubation with MV. Data expressed as mean ± SEM; n=3 distinct MV and HUVEC preparations. (C) Confocal microscopy image of HUVEC demonstrating endocytosis of fluorescent MV (n=3). BODIPY fluorescent (green) staining visualised on the micrographs identified distinct MV. AlexFlour 633 stained plasma membrane appears red while DAPI-stained nuclei appear blue (microscope calibrated daily). MV annotated with white arrows. One-way ANOVA and Bonferroni tests were used for comparison. **: p<0.01, ***: p<0.001.

Figure 5. Granulocyte-macrophage colony stimulating factor (GM-CSF) or interferon-γ (IFN-γ) generated microvesicles (MV) promote neutrophil and endothelial responses. (A) Either subset of MV (1 - 2 x 106 / ml) was incubated with freshly prepared neutrophils for 60 min, prior to addition of fluorescent heat killed E. Coli to assess the extent of phagocytosis by fluorescence plate reader. In some cases LPS (100 ng/ml) was added to the cells together with the MV. (B) MV (1 - 2 x 106 / ml), MV with A2MG antibody (0.1 - 5 μg/ml), cytokine supernatant free of MV (20 μl/ml) were incubated  in the presence of LPS - or LPS alone - with freshly prepared neutrophils (1x106ml) for 60 min, prior to addition of fluorescent heat killed E. Coli.  (C) MV were incubated with human umbilical vein endothelial cells (HUVEC) and the extent of permeability determined using fluorescent dextran (70,000 kDa) and fluorescent plate reader. D-G. Effect of MV on neutrophil-endothelium interaction under flow. HUVEC were incubated with LPS (100 ng/ml) for 4 h, prior to addition of MV (1 – 2 x 106 / ml) and flow of freshly prepared neutrophils. In all cases, data are mean ± SEM of 4 distinct preparations, these being MV, HUVEC or neutrophils, as required. LPS: lipopolysaccharide. One-way ANOVA and Bonferroni post-hoc tests were applied. *: p<0.05, **: p<0.01, ***: p<0.001 vs. corresponding LPS alone value.
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